<DOC>
	<DOCNO>NCT02472691</DOCNO>
	<brief_summary>This prospective , open-label , single-arm multi-center phase II study aim evaluate safety feasibility addition Lenalidomide ( investigational drug ) standard therapy Azacitidine DLI ( standard care ) first salvage therapy relapse MDS , CMML AML MDS-related change ( sAML , 20 % -30 % bone marrow blast , formerly RAEB-T ) allo-SCT . The start dose Lenalidomid 2.5 mg per day 21 day 7 day rest . The study incorporate 2 interim safety analyse 10 20 patient order find optimal safe dose Lenalidomide .</brief_summary>
	<brief_title>Azacitidine , Lenalidomide DLI Salvage Therapy MDS , CMML sAML Relapsing After Allo-HSCT</brief_title>
	<detailed_description>This prospective , open-label , single-arm multi-center phase II study aim evaluate safety feasibility addition Lenalidomide ( investigational drug ) standard therapy Azacitidine DLI ( standard care ) first salvage therapy relapse MDS , CMML AML MDS-related change ( sAML , 20 % -30 % bone marrow blast , formerly RAEB-T ) allo-SCT . Study Design : - prospective , open-label , single arm , multicenter phase-II trial - total patient sample size : 50 patient - number trial site : 6 locate Germany member EBMT Patients include time relapse first allo-SCT . Starting day 1 patient receive Azacitidine 75 mg/m2/d 7 day every 28 day 8 cycle . DLIs give cycle 4 , 6 8 . Lenalidomide also start day 1 21 day every 28 day maximum 8 cycle . The concomitant administration Aza Lenalidomide use since safety efficacy schedule demonstrate . Azacitidine DLI represent standard care set therefore consider investigational . As 5-Azacytidine give in-label , treatment may continue beyond 8 cycle . Additional DLIs may give accord investigator choice . However , avoid severe GvHD recommend give least one cycle 5-Azacytidine additional DLIs . The study incorporate dose escalate schedule Lenalidomide two safety interim analysis . A first interim analysis perform soon 10 patient treat Lenalidomide dose 2.5mg/day If dose limit toxicity observe cohort next cohort 10 patient treat 5 mg per day 21 day start day 1 . If dose limit toxicity occur study close . A second interim analysis perform soon 10 patient treat Lenalidomide adose 5mg/day 10th patient cohort either complete 4 cycle discontinue treatment whichever occur first . If dose limit toxicity observe cohort , dose 5 mg per day 21 day start day 1 chosen remain patient treat dose Lenalidomide . If dose limit toxicity occur patient treat 5mg per day remain patient treat Lenalidomide dose 2.5mg/day . A total number 50 patient treat . Independent dose level , Lenalidomide stop individually case GvHD ≥ grade II .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Chronic</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>First relapse de novo therapyrelated MDS , CMML AML myelodysplasiarelated change 2030 % bone marrowblast ( formerly RAEBT ) accord WHO 2008 classification first alloSCT ( relate unrelated donor &lt; 2 HLA mismatch ) Possibility DLI ( cord blood , haploidentical donor ) previous therapy relapse alloSCT ECOG performance status ≤ 2 study entry active GvHD treat systemic immunosuppression within 4 week inclusion uncontrolled infection inclusion Understand voluntarily sign informed consent form . Age 18 year time signing informed consent form . Able adhere study visit schedule protocol requirement . All female must acknowledge understood hazard necessary precaution associate use lenalidomide Relapse second allogeneic transplantation Any previous therapy ( chemotherapy , radiation investigational drug ) administer therapy relapse alloSCT previous transplantation cord blood , haploidentical donor related/unrelated donor ≥2 HLA mismatch Active GvHD require systemic immunosuppression within last 4 week Uncontrolled infection Any serious medical condition , laboratory abnormality , psychiatric illness would prevent subject signing informed consent form . Pregnant lactate female Any condition , include presence laboratory abnormality , place subject unacceptable risk he/she participate study confounds ability interpret data study mpaired renal function ( GFR &lt; 20 ml/min ) Impaired hepatic function Known hypersensitivity thalidomide , lenalidomide component treatment The development erythema nodosum characterize desquamate rash take thalidomide similar drug . Concurrent use anticancer agent treatment . Known positive HIV infectious hepatitis , type A , B C. Neuropathy ≥ grade 2 Prior history malignancy MDS AML ( except basal cell squamous cell carcinoma carcinoma situ cervix breast ) unless subject free disease ≥ 3 year Participation another study ongoing use unlicensed investigational product 28 day study enrollment end study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>relapse allogeneic transplantation</keyword>
	<keyword>MDS</keyword>
	<keyword>AML</keyword>
	<keyword>CMML</keyword>
	<keyword>DLI</keyword>
	<keyword>Azacitidine</keyword>
	<keyword>Lenalidomide</keyword>
	<keyword>C04.557.337.539.275</keyword>
	<keyword>C15.378.190.625</keyword>
	<keyword>C04.557.337.539.522</keyword>
</DOC>